Clinical Trial Update: A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 two-part study evaluating repeat-dose inhaled ETD001 in people with cystic fibrosis has completed, assessing efficacy, safety, tolerability, and pharm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ETD001

Snippet

Sponsor: Enterprise Therapeutics Ltd | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED